Oxford Properties Group has accomplished the acquisition and long-term lease again of 92 Crowley Drive. The asset is a 120,000 sq. foot state-of-the-art biomanufacturing facility below development and close to completion within the Boston life sciences submarket of Marlborough, MA. As a part of an actual property transaction with Resilience, Oxford will purchase the constructing and lease the property again to Resilience for as much as 30 years.
The acquisition grows Oxford’s present North American cGMP portfolio to 1.4 million sq. toes with a further growth pipeline of over 1 million sq. toes. Oxford’s North American cGMP platform and pipeline has 12 amenities throughout six markets, with the biggest focus within the Boston area totaling 775,000 sq. toes.
Upon completion this 12 months, 92 Crowley will likely be Resilience’s flagship facility within the US with state-of-the-art analytical and manufacturing know-how. The ability may have multi-modality manufacturing capabilities with devoted manufacturing suites and complementary workplace and warehouse area.
